

MH 14: 24

30 September 2020

Dear Pharmacists,

IMPLEMENTATION OF STEADY STATE ACCREDITATION CRITERIA FOR PHARMACY SPECIALIST

Following the closing of the grandfathering accreditation for the first five recognised specialties on 30 September 2013, PSAB has since implemented the transitional accreditation framework from 1 October 2013 which will officially end on 30 September 2020.

2. From **1 October 2020** onwards, all pharmacists who intend to apply to PSAB for specialist accreditation in the first five PSAB-recognised specialties¹ will need to fulfil the updated steady state accreditation criteria² as set out in **Annex A.** The criteria can also be accessed via the following link to PSAB website:

http://www.healthprofessionals.gov.sg/psab/specialist-accreditation/criteria-for-pharmacy-specialist-accreditation

- 4. Pharmacy Heads/Managers/Directors are required to forward this circular to the attention of all eligible pharmacists within their institutions for information.
- 5. For further enquiries, please contact PSAB via email at PSAB@spb.gov.sg.
- 6. Thank you.

ASSOC PROF LITA CHEW

CHAIRPERSON

PHARMACY SPECIALISTS ACCREDITATION BOARD (PSAB)

² For the two new specialties in Critical Care Pharmacy and Paediatric Pharmacy, the steady state accreditation criteria will apply from 1 January 2021 onwards after the closing of the current grandfathering accreditation phase.











¹ The first five specialties refer to:

¹⁾ Cardiology Pharmacy; 2) Geriatric Pharmacy; 3) Infectious Diseases Pharmacy; 4) Psychiatric Pharmacy; and 5) Oncology Pharmacy



ANNEX A

PSAB's Steady State Accreditation Criteria (w.e.f. 1 October 2020)

Applicants must meet the following criteria at the point of application for specialist accreditation:

- a) Fully registered with the SPC, holds a valid practising certificate, and is currently practising in Singapore;
- b) Possesses a relevant postgraduate qualification that is recognised by the PSAB;
- c) Possesses a valid specialty certification in the specialty applied for that is recognised by the PSAB*; and
- d) Has completed
 - i. one year of full-time residency training in broad-based pharmacotherapy that is recognised by the PSAB (i.e. National R1 programme); and
 - ii. one year of full-time residency training in the specialty applied for that is recognised by the PSAB (i.e. National R2 programme); and
- e) Has accumulated at least one year (continuous or otherwise) of specialty practice experience** in the specialty applied for after completion of R2 residency training, in the three years preceding the application.
- * Specialty certification refers to one of the following qualifications:

Cardiology Pharmacy

Board certification in Cardiology Pharmacy (BCCP) OR Pharmacotherapy with Added Qualifications in Cardiology from the Board of Pharmacy Specialties, USA

Geriatric Pharmacy

Board certification in Geriatric Pharmacy (BCGP) from the Board of Pharmacy Specialties, USA (formerly known as Board Certification in Geriatric Pharmacy from the Commission for Certification in Geriatric Pharmacy, USA)

Infectious Diseases Pharmacy

Board certification in Infectious Diseases Pharmacy (BCIDP) or Pharmacotherapy with Added Qualifications in Infectious Diseases from the Board of Pharmacy Specialties, USA

Psychiatric Pharmacy

Board certification in Psychiatric Pharmacy (BCPP) from the Board of Pharmacy Specialties, USA

Oncology Pharmacy

Board certification in Oncology Pharmacy (BCOP) from the Board of Pharmacy Specialties, USA

** Both patient care and specialty practice experience do not include any time spent in full-time postgraduate education and residency training programmes (both local and overseas).









